RecruitingPhase 4NCT07629557

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

Single-arm, Multi-center Study to Evaluate the Safety and Feasibility of Bilateral Epithelium-on Corneal Collagen Cross-linking With Epioxa™ HD/Epioxa™ and UV-A Irradiation Using the O2n™ System and Supplemental Oxygen Using the Boost Goggles® in Subjects With Keratoconus

Sponsor

Glaukos Corporation

Enrollment

15 participants

Start Date

May 11, 2026

Study Type

INTERVENTIONAL

Conditions

Keratoconus

Summary

Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.

Eligibility

Min Age: 13 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Riboflavin Ophthalmic Solutions and a medical device called UV-A Irradiation System for people with keratoconus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 13 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRiboflavin Ophthalmic Solutions

Riboflavin Ophthalmic Solutions

DEVICEUV-A Irradiation System

O2n UV-A Irradiation System

Locations(1)

Glaukos Investigative Site

Westerville, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07629557

Related Trials

A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases

NCT07780890

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

NCT074009521 location